Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD). A secondary objective is to characterize the safety and tolerability of utilizing quetiapine in patients with Borderline Personality Disorder.
Investigator initiated, 6-week, non-placebo controlled, non-randomized, open-label, single drug, single-center, medication trial.
Volunteers (n = 15) diagnosed with Borderline Personality Disorder using the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).
Subjects with Borderline Personality Disorder are washed out of all other medications. The subjects are then given the study drug at a dose within the drug's known therapeutic range.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|
- Symptom Checklist 90 scale (SCL-90-R) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
- Safety and tolerability will be measured at Baseline and weekly using the following scales: Simpson-Angus Extrapyramidal Side Effect Scale (SAS), Barnes Akathisia Scale (BAS), and Abnormal Involuntary Movement Scale (AIMS). [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||May 2005|
|Study Completion Date:||May 2008|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
Quetiapine at dosage of 50 to 150 mg
Drug: Quetiapine Fumarate
Dosage can vary from 50 to 150 mg at PI's discretion
Other Name: Seroquel
Show Detailed Description
|United States, New Jersey|
|University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry|
|Cherry Hill, New Jersey, United States, 08002-2000|
|Principal Investigator:||David J Rissmiller, DO||University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine|